Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
* Reuters is not responsible for the content in this press release.
Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor
Conferences
PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS) management will present at the 3rd Annual Citi Biotech Day
being held September 8, 2008, at the Citi Executive Conference Center, New
York, NY. Management will also present at the Morgan Stanley Global
Healthcare Unplugged Conference on September 9, 2008, at the Grand Hyatt
Hotel, New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer,
will provide a brief overview of the company followed by a question and answer
session at both conferences.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by Bukwang
Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral
treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in
combination with Pegasys(R) plus Copegus(R) through a strategic collaboration
with Roche. Racivir, which is being developed for the treatment of HIV in
combination with other approved HIV drugs, has completed a Phase 2 clinical
trial. Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Kurt Leutzinger
Chief Financial Officer
kurt.leutzinger@pharmasset.com
Office: +1 (609) 613-4110
SOURCE Pharmasset, Inc.
Kurt Leutzinger, Chief Financial Officer of Pharmasset, Inc., +1-609-613-4110,
kurt.leutzinger@pharmasset.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters